137 related articles for article (PubMed ID: 9612676)
21. Prostatic adenocarcinoma diagnosed by prostate-specific antigen analysis of pleural fluid.
Brown GA; Ginsberg PC; Harkaway RC
Urol Int; 1998; 60(3):197-8. PubMed ID: 9644796
[TBL] [Abstract][Full Text] [Related]
22. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.
Montironi R; Mazzucchelli R; Marshall JR; Bartels PH
J Clin Pathol; 1999 Nov; 52(11):793-803. PubMed ID: 10690166
[No Abstract] [Full Text] [Related]
24. Chemoprevention of prostate cancer: breakthroughs and controversies.
Kim J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1517-22. PubMed ID: 20942621
[No Abstract] [Full Text] [Related]
25. Prostate-specific antigen and screening for prostate cancer: much ado about something?
Pollack HM; Resnick MI
Radiology; 1993 Nov; 189(2):353-6. PubMed ID: 7692463
[No Abstract] [Full Text] [Related]
26. Prostate cancer screening. Why the controversy?
Walther PJ
Surg Oncol Clin N Am; 1995 Apr; 4(2):315-34. PubMed ID: 7540938
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer: to screen or not to screen?
Oncology (Williston Park); 1997 Mar; 11(3):325-6, 329-30. PubMed ID: 9109125
[No Abstract] [Full Text] [Related]
28. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
29. Informing patients about prostate cancer screening: identifying and meeting the challenges while the evidence remains uncertain.
Partin MR; Wilt TJ
Am J Med; 2002 Dec; 113(8):691-3. PubMed ID: 12505123
[No Abstract] [Full Text] [Related]
30. Prostate adenocarcinoma manifesting as generalized lymphadenopathy.
Moura FM; Garcia LT; Castro LP; Ferrari TC
Urol Oncol; 2006; 24(3):216-9. PubMed ID: 16678051
[TBL] [Abstract][Full Text] [Related]
31. Re: Kim et al.: detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/ml (Urology 2010;76:919-922).
Shenoy SP; Marla PK; Adappa KK
Urology; 2011 Apr; 77(4):1013-4; author reply 1014. PubMed ID: 21477737
[No Abstract] [Full Text] [Related]
32. Chemoprevention strategies for prostate cancer.
Bosland MC; McCormick DL; Melamed J; Walden PD; Zeleniuch-Jacquotte A; Lumey LH
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S18-27. PubMed ID: 12570331
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer: 4. Screening.
Meyer F; Fradet Y
CMAJ; 1998 Oct; 159(8):968-72. PubMed ID: 9834724
[No Abstract] [Full Text] [Related]
34. Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening.
Sandhu S; Morris R; Matveev V; Kaisary AV
BMJ; 1996 Mar; 312(7032):709; author reply 709-10. PubMed ID: 8597766
[No Abstract] [Full Text] [Related]
35. Patient education. Prostate cancer.
Frydenberg M
Aust Fam Physician; 2003 Jun; 32(6):428. PubMed ID: 12833768
[No Abstract] [Full Text] [Related]
36. Present and future management of prostate cancer.
de Vere White R
Cancer Biother Radiopharm; 2000 Apr; 15(2):121-5. PubMed ID: 10803316
[No Abstract] [Full Text] [Related]
37. Prostate-specific antigen density and age-specific prostate-specific antigen values: the solution of prostate cancer screening?
Paul R; Breul J; Hartung R
Eur Urol; 1995; 27(4):286-91. PubMed ID: 7544733
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
39. The controversy of prostate screening.
McDougall GJ; Weber BA; Dziuk TW; Heneghan R
Geriatr Nurs; 2000; 21(5):245-8; quiz 249. PubMed ID: 11035306
[TBL] [Abstract][Full Text] [Related]
40. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Collette L; Buyse M; Burzykowski T
J Clin Oncol; 2007 Dec; 25(35):5673-4; author reply 5674. PubMed ID: 18065747
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
